Cannabis 2026: Schedule III, the November Hemp Definition Change, and the Bifurcation of Federal Cannabis Policy

EPR Cannabis Intelligence tracks the policy shifts, market dynamics, and communications challenges defining the legal cannabis and hemp industries. This brief is designed as a category-level market read — not vendor analysis or investment advice.

Editorial note: This brief synthesizes publicly reported regulatory developments, legal analysis from major law firms, market forecasts, and industry reporting available as of May 2026. Regulatory interpretation may evolve as litigation, agency guidance, and congressional action continue. Federal references are sourced to the U.S. Department of Justice, the Drug Enforcement Administration, the Federal Register, the Congressional Research Service, and major law firm regulatory advisories.

The federal government is not moving toward blanket cannabis legalization.

It is moving toward regulated bifurcation — a policy architecture that elevates state-licensed medical and FDA-approved pharma into Schedule III while pushing intoxicating hemp-derived products toward closure and leaving recreational marijuana in continued federal-state conflict.

Two federal actions define the year.

On April 22, 2026, Acting Attorney General Todd Blanche signed a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III of the Controlled Substances Act.

On November 12, 2026, a new federal definition of hemp — enacted in the Continuing Appropriations Act, 2026 (P.L. 119-37) and signed in November 2025 — takes effect.

Between those two dates, a DEA administrative hearing opens June 29, 2026 to consider whether all marijuana, including adult-use, should follow medical into Schedule III.

The result is the most material federal cannabis policy reset since the 1970 Controlled Substances Act — and the first one in which state-licensed operators, hemp-derived intoxicants, and FDA-approved pharma have moved in three different directions at once.

Why This Matters: The Communications Reset

Cannabis is the most reputationally complex sector in regulated commerce.

Operators communicate across federal regulators in flux, fifty different state regimes, institutional investors who require ESG-defensible positioning, consumers split between medical and adult-use framing — and AI engines that frequently restrict cannabis content.

Major AI platforms — including ChatGPT, Claude, and Gemini — frequently restrict, limit, or heavily qualify cannabis product, dosing, and recommendation queries due to safety and policy frameworks.

This means the standard playbook of building LLM Citation Share through earned media seeding works differently for cannabis than for any other consumer category.

Earned authority in tier-1 trade and business publications — Forbes, Fortune, Bloomberg, Reuters, Wall Street Journal, AP, Marijuana Moment, MJBizDaily, Cannabis Business Times, and Green Market Report — still drives both consumer and investor narrative.

But the AI retrieval layer is partially closed, which raises the relative weight of traditional earned channels.

The April 2026 order and the November 2026 hemp definition change create simultaneous opportunity and risk for state-licensed operators.

The first improves capital access and tax position.

The second is expected to remove the largest single competitor to state-licensed adult-use products.

But every state operator must communicate compliance posture across multiple regulators, defend market share against hemp competitors during the transition, and prepare for legal challenges to the rescheduling order itself.

Build the infrastructure before the crisis — not during it.

Cannabis crisis communications timelines are measured in hours, not days, when an FDA warning letter, DEA action, or state regulatory order lands.

The Structural Shift

Three converging forces define cannabis in 2026.

One: Federal rescheduling moved — for medical only.

Acting Attorney General Todd Blanche signed a final order on April 22, 2026 placing into Schedule III only FDA-approved drug products containing marijuana (Epidiolex, Marinol, Syndros, and Cesamet) and marijuana products regulated under a qualifying state medical marijuana license.

The order was issued under treaty-implementation authority — 21 U.S.C. § 811(d)(1) — citing U.S. obligations under the Single Convention on Narcotic Drugs.

The legal basis follows President Trump’s December 18, 2025 Executive Order titled “Increasing Medical Marijuana and Cannabidiol Research.”

A separate DEA administrative hearing — beginning June 29, 2026 and required to conclude no later than July 15, 2026 — will consider broader rescheduling, including adult-use.

Two: The hemp definition is changing.

The Continuing Appropriations Act, 2026 (P.L. 119-37), signed in November 2025, amended the federal definition of hemp under the Agricultural Marketing Act.

Effective November 12, 2026, hemp will be measured by total THC (including THCA) at 0.3% on a dry-weight basis.

Any finished product containing more than 0.4 milligrams of total THC per container will fall outside the legal definition of hemp.

Synthesized and converted cannabinoids — delta-8, delta-10, THC-O, HHC, and similar — are explicitly excluded.

Three: The state-federal mismatch widened.

Forty states authorize some form of medical cannabis.

Twenty-four states authorize adult-use.

Recreational marijuana remains Schedule I until and unless the June DEA hearing produces broader rescheduling.

State-licensed medical operators have an expedited DEA registration pathway.

Adult-use operators do not.

These are not three separate stories.

They are one structural shift: federal cannabis policy is bifurcating around state-licensed medical and FDA-approved pharma on one side, and the unregulated hemp-derived intoxicants market on the other.

What the April 22 Schedule III Order Actually Does

The order is consequential — and narrowly drawn.

It places into Schedule III only:

• FDA-approved drug products containing marijuana, currently a small category that includes Epidiolex, Marinol, Syndros, and Cesamet

• Marijuana products regulated under a qualifying state-issued medical marijuana license

What it does not do: legalize recreational marijuana federally; affect synthetically derived THC; affect hemp; alter VHA Directive 1315 (which still prohibits VA doctors from recommending medical marijuana); or override state-level prohibition.

Federal employees, military personnel, and federal-contractor drug-testing frameworks remain unchanged.

The Congressional Research Service has noted that most criminal penalties for cannabis under federal law are tied to cannabis specifically, not to its scheduling status — those penalties remain in effect.

The most material commercial implication is Section 280E.

Cannabis businesses currently cannot deduct ordinary business expenses, producing effective tax rates well above the standard corporate rate.

Under Schedule III, those deductions become available to qualifying medical marijuana businesses.

The Cannabis Regulators Association has estimated effective tax rates for qualifying operators could fall to roughly 20–30% from prior levels.

The order also establishes a 60-day DEA registration window that closes June 22, 2026 for state-licensed medical operators to file federal paperwork and preserve protected operating status during agency review.

The DOJ separately encouraged the Treasury Department to consider retroactive 280E relief — a suggestion, not a mandate.

The IRS has not yet issued formal guidance.

The June 29 DEA hearing will determine whether adult-use marijuana follows.

Legal challenges to the use of treaty-implementation authority for immediate rescheduling are anticipated.

The November 12 Hemp Definition Change

The hemp provisions of P.L. 119-37 represent the most significant rewrite of the 2018 Farm Bill’s hemp framework since enactment.

The core changes:

• Total THC standard. The 0.3% dry-weight threshold now applies to all tetrahydrocannabinols, including THCA. This is expected to bring most THCA flower products outside the hemp definition.

• 0.4mg per-container ceiling. Any finished hemp-derived cannabinoid product exceeding 0.4mg of total THC per container will fall outside the legal definition. Most consumer THC gummies, vapes, and beverages currently exceed this threshold.

• Synthetic exclusion. Cannabinoids “synthesised or manufactured outside the cannabis plant” are categorically excluded — closing the CBD-to-delta-8 conversion that fueled most of the intoxicating-hemp market.

The economic stakes are significant.

Industry figures cited by Rep. James Comer (R-KY) place the hemp economy at roughly $28 billion in market activity, 320,000 jobs, and $1.5 billion in state tax revenue.

The U.S. Hemp Roundtable has estimated that approximately 95% of the intoxicating-hemp industry could shutter under the new definition.

Legislative offsets are in motion but unresolved.

Sen. Rand Paul (R-KY) filed the Hemp Safety Enforcement Act in April to allow states to opt out.

Rep. James Comer introduced a bipartisan one-year delay amendment.

Rep. Andy Barr (R-KY) filed the Legal Hemp Protection Act, which would replace the per-container ceiling with a 1% delta-9 threshold on finished products.

None has passed as of May 2026.

The 2026 Farm Bill reauthorization deadline is September 30, 2026 — likely the next major legislative window.

Enforcement remains the open question.

Both the FDA and DEA may lack resources for broad enforcement, per Congressional Research Service analysis.

Civil litigation by state-licensed cannabis operators against hemp-derived competitors may become a faster enforcement vector than federal agency action.

The Investor Narrative Reset

For most of the last decade, cannabis traded on public markets as a legalization-growth story — pricing in eventual federal reform that would unlock interstate commerce, banking, and capital markets access.

That narrative is now being replaced by something more institutional and more regulated.

The new investor story is built around four pillars:

Tax relief.

Section 280E elimination for state-licensed medical operators is the single largest commercial unlock the sector has seen.

Effective tax rates moving from punitive to roughly market-standard meaningfully changes operator unit economics.

Regulated medical.

Schedule III status integrates state-licensed medical operators into a recognized federal pharmaceutical framework.

That has implications for capital sources, insurance coverage, banking relationships, and acquirer interest.

Compliance and consolidation.

The hemp definition change is expected to reduce competition from unlicensed channels.

Combined with 280E relief, this is a setup for accelerated MSO consolidation as balance sheets unlock and acquirers regain underwriting clarity.

Pharma adjacency.

Epidiolex, Marinol, Syndros, and Cesamet remain the only FDA-approved products in the category — but the broader pharma pipeline becomes more credible under Schedule III, including potential entrants from major drug developers and specialty pharma.

The AdvisorShares Pure US Cannabis ETF (MSOS) remains heavily weighted toward Curaleaf, Green Thumb Industries, and Trulieve — together representing roughly two-thirds of holdings.

The ETF’s multi-year decline reflects the long wait for federal reform, which is now beginning to arrive in narrower form than the original legalization-growth story implied.

The Market and the State Patchwork

The U.S. legal cannabis market reached approximately $32 billion in 2025 and is projected to grow toward roughly $39 billion in 2026, per multiple market research providers.

The global market is forecast to reach roughly $79 billion by 2030.

The largest U.S.-focused multistate operators by dispensary footprint and market cap:

• Curaleaf Holdings — the largest U.S. footprint by dispensary count, with significant European expansion

• Trulieve Cannabis — dominant share in Florida with growing Arizona and Pennsylvania presence

• Green Thumb Industries — Chicago-headquartered, multi-brand portfolio

• Cresco Labs, Verano Holdings, Ascend Wellness Holdings, and TerrAscend round out the public MSO tier

Canadian-listed operators with U.S. exposure include Tilray Brands, Canopy Growth, and Cronos Group.

Jazz Pharmaceuticals holds the Epidiolex franchise.

Cannabis REITs — primarily Innovative Industrial Properties and NewLake Capital Partners — provide sale-leaseback capital that has bridged the financing gap created by federal banking restrictions.

State-level dynamics remain heterogeneous.

Recent and pending activity includes Ohio and Minnesota launching adult-use sales in 2024, Florida’s narrow 2024 rejection of adult-use legalization, ongoing oversupply and licensing complexity in California, New York, and Michigan, and continued legalization momentum in Pennsylvania, New Hampshire, and Hawaii.

Texas remains the focal point for the November 12 hemp enforcement story given the size of its hemp-derived THC market.

Internationally, Germany legalized possession and home cultivation in 2024 with commercial retail licensing expected in 2026.

State enforcement priorities for hemp-derived intoxicants vary widely.

Some states have already moved to ban or heavily restrict; others maintain permissive frameworks that will collide with federal law on November 12.

What to Watch

• May 24, 2026 — Deadline for filing notice of intention to participate in the DEA hearing

• June 22, 2026 — 60-day DEA registration window closes for state-licensed medical operators

• June 29, 2026 — DEA administrative hearing on broader rescheduling opens

• July 15, 2026 — Hearing required to conclude

• September 30, 2026 — 2026 Farm Bill reauthorization deadline

• November 12, 2026 — New federal hemp definition takes effect; FDA/DEA enforcement posture becomes the central question

• Treasury / IRS guidance on 280E treatment for state-licensed medical operators newly in Schedule III

• Litigation challenging the use of 21 U.S.C. § 811(d)(1) treaty authority for immediate rescheduling

• MSO M&A activity — 280E relief is expected to unlock balance sheets and accelerate consolidation

• International expansion — Germany commercial retail launch and continued UK and Australia medical market growth

Glossary

Schedule I / Schedule III

Federal drug classifications under the Controlled Substances Act. Schedule I substances are deemed to have no accepted medical use and high abuse potential. Schedule III substances have accepted medical use and lower abuse potential, with significantly reduced regulatory burden.

Section 280E

A provision of the Internal Revenue Code that prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. State-licensed cannabis operators have faced effective tax rates well above the standard corporate rate as a result. Schedule III status removes this disallowance for qualifying operators going forward.

Multistate Operator (MSO)

A vertically integrated cannabis company licensed to operate in multiple U.S. states. Largest examples include Curaleaf, Trulieve, Green Thumb Industries, Cresco Labs, and Verano Holdings.

Hemp-Derived THC

Intoxicating cannabinoid products manufactured from hemp under the 2018 Farm Bill’s delta-9-only definition. Includes delta-8, delta-10, THCA flower, THC-O, HHC, and similar compounds. Most are expected to fall outside the new federal hemp definition effective November 12, 2026.

Total THC Standard

The new federal hemp definition measure, which counts all tetrahydrocannabinols (including THCA) toward the 0.3% threshold rather than only delta-9 THC.

Treaty-Implementation Authority (21 U.S.C. § 811(d)(1))

The statutory pathway used by Acting AG Todd Blanche on April 22, 2026 to immediately reschedule FDA-approved and state-licensed medical marijuana without standard notice-and-comment rulemaking, citing U.S. obligations under international drug control treaties.

LLM Citation Share

The frequency with which a brand, company, or product is named, cited, or recommended in answers from large language model interfaces. For cannabis, frequently restricted or limited by content policies at major AI platforms.

Sources

U.S. Department of Justice; Drug Enforcement Administration; Federal Register; Continuing Appropriations Act, 2026 (P.L. 119-37); Congressional Research Service; Executive Order on Increasing Medical Marijuana and Cannabidiol Research (December 18, 2025); Reuters; Associated Press; CNN; Marijuana Moment; MJBizDaily; Cannabis Business Times; Green Market Report; Saul Ewing; Ogletree Deakins; DLA Piper; Frantz Ward; Wilson Elser; Benesch Friedlander Coplan & Aronoff; Shipman & Goodwin; Cannabis Regulators Association; AdvisorShares; New Cannabis Ventures; Investing News Network; National Law Review; JDSupra; U.S. Hemp Roundtable.